Impacto de la albúmina en la sobrevida de los pacientes ancianos con linfoma de células grandes B difuso
DOI:
https://doi.org/10.35434/rcmhnaaa.2024.174.2215Palabras clave:
Linfoma células grandes B difuso, albúmina, ancianosResumen
Introducción: Linfoma de células grandes B difuso es el subtipo de linfoma más frecuente. La albúmina demuestra ser un factor pronóstico en este subtipo de linfoma. Objetivo: El objetivo de este estudio es evaluar el rol de la albúmina en la sobrevida de los pacientes ancianos con linfoma de células grandes B difuso en un hospital general del Perú. Material y métodos: Este fue un estudio retrospectivo de 62 pacientes con linfoma de células grandes B difuso con edad de 80 años o más. Resultados: En el análisis multivariado, enfermedad bulky (HR= 3,1, 95% 1,5-6,4; p=0,003) y albúmina (HR 3.8 95% 1,9-7,6; p=0,001) fueron factores asociados a sobrevida. Conclusiones: Enfermedad bulky y albúmina fueron factores asociados a sobrevida global en pacientes con linfoma de células grandes B difuso de 80 años o mayores.
Descargas
Métricas
Citas
d'Amore F, Brincker H, Christensen BE, Thorling K, Pedersen M, Nielsen JL, et al: Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-study group. Ann Oncol 3: 379-386, 1992. doi: 10.1093/oxfordjournals.annonc.a058211.
Stengel A, Baer C, Walter W, Meggendorfer M, Kern W, Haferlach T et al. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. Blood Adv. 2021 Nov 9;5(21):4426-4434. doi: 10.1182/bloodadvances.2021004668.
Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 2020;135:2041-8.doi: 10.1182/blood.2019002729.
Abdulla M, Hollander P, Pandzic T, et al. Cell-of-origin determined by both gene expression profiling and immunohistochemistry is the strongest predictor of survival in patients with diffuse large B-cell lymphoma. Am J Hematol 2020;95:57-67.doi: 10.1002/ajh.25666.
Yang J, Guo X, Hao J, et al. The Prognostic Value of Blood-Based Biomarkers in Patients With Testicular Diffuse Large B-Cell Lymphoma. Front Oncol 2019;9:1392.doi: 10.3389/fonc.2019.01392
Miao Y, Medeiros LJ, Xu-Monette ZY, et al. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Front Oncol 2019;9:107.doi: 10.3389/fonc.2019.00107.
Roh J, Jung J, Lee Y, et al. Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell Lymphoma. Front Oncol 2020;10:329.doi: 10.3389/fonc.2020.00329
Chihara D, Oki Y, Ine S, et al. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 2009;50:1999-2004. doi: 10.3109/10428190903318311.
Watanabe T, Kinoshita T, Itoh K, et al. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma 2010;51:813-21.doi: 10.3109/10428191003721359.
Zhu YJ, Huang JJ, Xia Y, et al. Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. Int J Hematol 2011;94:178-84.doi: 10.1007/s12185-011-0898-4.
Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006;107:4643-9.doi: 10.1182/blood-2005-11-4659.
Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460-8. doi: 10.1016/S1470-2045(11)70069-9.
Kaneko H, Shimura K, Yoshida M, Matsumoto Y, Kobayashi T, Uchiyama H, Kuroda J, Taniwaki M. Serum Albumin Levels Strongly Predict Survival Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Combined Chemotherapy. Int J Hematol Oncol Stem Cell Res. 2022 Jan 1;16(1):1-8. doi: 10.18502/ijhoscr.v16i1.8433.
Arcari A, Cavallo F, Puccini B, Vallisa D. New treatment options in elderly patients with Diffuse Large B-cell Lymphoma. Front Oncol. 2023 Jul 3;13:1214026. doi: 10.3389/fonc.2023.1214026.
Zhou Q, Wei Y, Huang F, et al. Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. Int J Hematol 2016;104:485-90. doi: 10.1007/s12185-016-2052-9.
Hu X, Feng X, Wang H, Miao Y, Lian X, Gao Q, et al. Association between serum albumin levels and survival in elderly patients with diffuse large B-cell lymphoma: a single-center retrospective study. Transl Cancer Res. 2023;12(6):1577-1587. doi: 10.21037/tcr-23-503
McMillan DC, Watson WS, O'Gorman P, et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001;39:210-3. doi 10.1207/S15327914nc392_8
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 2010;9:69. doi 10.1186/1475-2891-9-69
Brenner DA, Buck M, Feitelberg SP, et al. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 1990;85:248-55. doi 10.1172/JCI114419
Aviles A, Yañez J, López T, et al. Malnutrition as an adverse prognostic factor in patients with diffuse large cell lymphoma. Arch Med Res 1995;26:31-4. PMID: 7711444.
Başcı S, Yiğenoğlu TN, Bakırtaş M, Uncu Ulu B, Yaman S, Dal MS, Kızıl Çakar M, Altuntaş F. The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor? Leuk Res. 2021 Mar;102:106521. doi: 10.1016/j.leukres.2021.106521
Descargas
Publicado
Cómo citar
Licencia
Derechos de autor 2025 Brady E. Beltran
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
